Abstract:Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intracellular signaling domain responsible for T cell activation, and a hinge that joins these two domains. Continuous improvement has been made in CARs, now in their fifth generation, particularly in the intracellular signaling domain responsible for T cell activation. CAR T cell therapy has revolutionized the treatment of hematologic malignancies. Nonetheless, the use of CAR T cell therapy for solid tumors has not attained comparable levels of success. Here we review the challenges in achieving effective CAR T cell therapy in solid tumors, and emerging CAR T cells that have shown great promise for non-small cell lung cancer (NSCLC). A growing number of clinical trials have been conducted to study the effect of CAR T cell therapy on NSCLC, targeting different types of surface antigens. They include epidermal growth factor receptor (EGFR), mesothelin (MSLN), prostate stem cell antigen (PSCA), and mucin 1 (MUC1). Potential new targets such as erythropoietin-producing hepatocellular carcinoma A2 (EphA2), tissue factor (TF), and protein tyrosine kinase 7 (PTK7) are currently under investigation in clinical trials. The challenges in developing CAR T for NSCLC therapy and other approaches for enhancing CAR T efficacy are discussed. Finally, we provide our perspective on imaging CAR T cell action by reviewing the two main radionuclide-based CAR T cell imaging techniques, the direct labeling of CAR T cells or indirect labeling via a reporter gene.

CAR T cells for solid tumors – developments to watch in 2023

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Bright future or blind alley? CAR-T cell therapy for solid tumors

Prospects and challenges for use of CAR T cell therapies in solid tumors

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

CAR-T in cancer therapeutics and updates

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

CAR T cells in solid tumors: challenges and opportunities

State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?

Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress

Developing CAR T-Cell Therapies for Pediatric Solid Tumors

A long way to the battlefront: CAR T cell therapy against solid cancers.

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer

CAR T cell immunotherapy in hematology and beyond

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

[Chimeric antigen receptors in oncology: clinical applications and new developments]